GlassScriptPhysician profile
Ramiro David Yepez
NPI 1477657252
$2,911.21
in general payments reported to CMS, 2019-2025
18 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $230 · 2021: $64.43 · 2022: $541 · 2023: $344 · 2024: $936 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $495.38 | 2024-2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $336.03 | 2023-2024 | Nuzyra |
| Kerecis Limited | $278.78 | 2020-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Convatec INC. | $278.23 | 2023-2024 | |
| Treace Medical Concepts, INC. | $236.94 | 2022-2025 | |
| Nevro Corp. | $235.83 | 2022 | |
| Paragon 28, INC. | $203.16 | 2019-2024 | Hammertube Sterile Implant Kits, Precision Guide Lapidus |
| Integra Lifesciences Corporation | $195.00 | 2019-2020 | |
| Ossio INC | $155.37 | 2022 | |
| Zimmer Biomet Holdings, INC. | $89.57 | 2021-2022 | |
| Smith+Nephew, INC. | $85.52 | 2020-2022 | |
| Alfasigma USA, INC. | $67.82 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.43 | 2019 | |
| Abbott Laboratories | $54.17 | 2019 | |
| Stryker Corporation | $50.67 | 2025 | Augment Injectable |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $38.20 | 2019-2021 | |
| Heron Therapeutics, INC. | $28.38 | 2023 | Zynrelef |
| Merck Sharp & Dohme LLC | $26.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramiro Yepez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.